Akorn (AKRX) JV Announces FDA Approval For Sterile Vancomycin HCl USP
More News related to AKRX
- Akorn (AKRX) Posts Q3 Loss of $0.06, Beats By 2c
- Akorn Reports Third Quarter 2009 Financial Results; Launches Two New Products: Ketorolac Tromethamine Ophthalmic and Hydralazine HCL
- Trading Radar for 11/10: Tyco Int. (TYC), ArvinMeritor (ARM), Clearwire (CLWR), American Apparel (APP) Report
- Akorn, Inc. Announces Third Quarter 2009 Earnings Release and Conference Call Information
- Akorn (AKRX) Files Shelf Offering of Up To 13.3M Shares
More News related to FDA
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Needham Lifts Price Target on Dyax (DYAX) to $8
- Novo Nordisk (NVO) Atophic Vaginitis Treatment Approved by U.S. FDA
- AEterna (AEZS) Announces FDA Fast Track Status for KRX-0401
- Keryx (KERX) Granted FDA Fast Track Designation for KRX-0401
Akorn-Strides, LLC announced that the FDA has granted approvals for two Abbreviated New Drug Applications for Sterile Vancomycin HCl USP, 500 mg/vial, 1 g/vial and Sterile Vancomycin HCl USP, 5 g/vial Pharmacy Bulk Package.
Akorn-Strides, LLC is a Joint Venture that was formed in 2004 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited.
Sterile Vancomycin HCl is an antibiotic indicated for the treatment of potentially life-threatening infections which cannot be treated with other effective antimicrobial drugs, including the penicillins and cephalosporins.
Related Categories
FDAStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
